Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GAL1906 (hyaluronic acid)
- Development stage
- Unknown
- Lead developer
- Galderma
- Administration
- Intradermal
01
Overview
GAL1906 is a stabilized hyaluronic acid-based dermal filler developed by Galderma, specifically identified as Restylane Skinboosters Vital. It is formulated using Galderma's proprietary NASHA (Non-Animal Stabilized Hyaluronic Acid) technology, which involves minimal cross-linking to create a gel that closely resembles natural hyaluronic acid. GAL1906 is primarily indicated for the correction of wrinkles and the improvement of skin hydration and elasticity in the décolletage (chest) area. Clinical evaluation has focused on its effectiveness in reducing wrinkle severity and ensuring that the presence of the filler does not interfere with the interpretation of mammograms.
- Brand names
- Restylane Skinboosters VitalRestylane
- Other names
- Restylane VitalNASHA
Beyond the preview
Go deeper on GAL1906 (hyaluronic acid).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GAL1906 (hyaluronic acid).